Candel Therapeutics/$CADL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Candel Therapeutics
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Ticker
$CADL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
38
ISIN
US1374041093
Website
CADL Metrics
BasicAdvanced
$278M
-
-$1.08
-0.91
-
Price and volume
Market cap
$278M
Beta
-0.91
52-week high
$9.13
52-week low
$4.25
Average daily volume
976K
Financial strength
Current ratio
4.641
Quick ratio
4.592
Long term debt to equity
1.555
Total debt to equity
14.614
Interest coverage (TTM)
-18.78%
Management effectiveness
Return on assets (TTM)
-32.31%
Return on equity (TTM)
-98.14%
Valuation
Price to book
3.66
Price to tangible book (TTM)
3.66
Price to free cash flow (TTM)
-7.545
Growth
Earnings per share change (TTM)
-16.32%
3-year earnings per share growth (CAGR)
-8.47%
CADL News
AllArticlesVideos
Candel Therapeutics get FDA's RMAT designation for prostate cancer therapy
Proactive Investors·1 week ago
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
GlobeNewsWire·1 week ago
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Candel Therapeutics stock?
Candel Therapeutics (CADL) has a market cap of $278M as of June 06, 2025.
What is the P/E ratio for Candel Therapeutics stock?
The price to earnings (P/E) ratio for Candel Therapeutics (CADL) stock is 0 as of June 06, 2025.
Does Candel Therapeutics stock pay dividends?
No, Candel Therapeutics (CADL) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Candel Therapeutics dividend payment date?
Candel Therapeutics (CADL) stock does not pay dividends to its shareholders.
What is the beta indicator for Candel Therapeutics?
Candel Therapeutics (CADL) has a beta rating of -0.91. This means that it has an inverse relation to market volatility.